Klin Onkol 1998; 11(2): 41-46.
Summary: The first report summarising results of phase I clinical trials for ondansetron, a serotonin receptor antagonist (5-HT,), was published just ten years ago. In induction of ondansetron into clinical practice was a therapculic breakthrough enabling intensification óf chemotherapy and radiotherapy. This paper summarises updated information on the mechanism of action of 5HT3 antagonists and their antiemetic properties. Pharmacokinetic parameters and analysis of clinical studies (international and local), which were performed in the Czech and Slovak republics in 1993 - 1097, are discussed.
